溶瘤病毒诱导肿瘤凋亡及激活抗肿瘤免疫机制的研究进展

doi:10.11904/j.issn.1002-3070.2021.05.014

摘要/Abstract

摘要： 恶性肿瘤被认为是细胞不受控制的生长和增殖。肿瘤细胞为避免被清除,形成多种自我保护机制,其中包括对细胞凋亡的抵抗,以及通过影响免疫系统形成的免疫逃逸。这使得肿瘤细胞具有很强的增殖能力,并产生高度的侵袭、转移倾向。部分肿瘤患者,在接受治疗时,效果并不理想或在治疗后,仍然出现复发、转移的情况。因此,新的治疗方式的研发是当务之急。溶瘤病毒的发现为恶性肿瘤的治疗提供了新思路。随着对溶瘤病毒的深入研究,人们发现溶瘤病毒可以通过多种机制发挥抗肿瘤作用,除了在肿瘤细胞中复制、引起肿瘤细胞的裂解,还能够诱导肿瘤细胞发生凋亡。此外,溶瘤病毒通过激活免疫细胞从而,启动抗肿瘤免疫应答并改变肿瘤细胞周围的免疫微环境来发挥长效的抗肿瘤作用,并抑制未感染病毒的肿瘤细胞。溶瘤病毒能够同时针对细胞凋亡以及机体抗肿瘤免疫发挥作用使其可以有效地对抗肿瘤细胞的凋亡抵抗和免疫逃避,使得它作为潜在的抗肿瘤治疗方式受到广泛关注。本文旨在介绍溶瘤病毒通过诱导肿瘤细胞凋亡以及激活免疫系统进而发挥抗肿瘤作用的相关研究进展。

关键词: 恶性肿瘤, 溶瘤病毒, 细胞凋亡, 免疫逃逸, 免疫检查点

Abstract: Malignant tumor is considered as the uncontrolled growth and reproduction of cells.In order to avoid being eliminated,tumor cells form a variety of self-protection mechanisms,including resistance to apoptosis and immune escape by affecting the immune system.This makes tumor cells that have a strong ability to proliferate and have a high tendency of invasion and metastasis.Some patients,in the treatment,the effect is not ideal or after treatment,still appears recurrence and metastasis.Therefore,the research and development of new treatment methods are an urgent task.The discovery of oncolytic virus provides a new idea for the treatment of malignant tumors.With the deepening of the research on oncolytic virus,it is found that oncolytic virus can play an anti-tumor role through a variety of mechanisms.In addition to replicating in tumor cells and causing tumor cell lysis,it can also induce tumor cell apoptosis.Besides,oncolytic virus can activate immune cells,initiate anti-tumor immune response and change the immune microenvironment around tumor cells,which can play a long-term anti-tumor effect and inhibit uninfected tumor cells.Oncolytic virus plays a role in both cell apoptosis and anti-tumor immunity,which can effectively resist apoptosis and immune evasion of tumor cells,making a potential anti-tumor therapy.This article aims to introduce the research progress of oncolytic virus through inducing tumor cell apoptosis and activating immune system.

Key words: Malignant tumor, Oncolytic virus, Apoptosis, Immune escape, Immune checkpoint

中图分类号:

R730.5

金升烨, 庞达. 溶瘤病毒诱导肿瘤凋亡及激活抗肿瘤免疫机制的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 462-467.

JIN Shengye, PANG Da. Research progress in the mechanism of oncolytic virus inducing tumor apoptosis and activating anti-tumor immunity[J]. Journal of Practical Oncology, 2021, 35(5): 462-467.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.05.014

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I5/462

参考文献

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 SM OB,Mathis JM.Oncolytic virotherapy for breast cancer treatment[J].Curr Gene Ther,2018,18(4):192-205.
3 Mozaffari Nejad AS,Fotouhi F,Mehrbod P,et al.Oncolytic effects of Hitchner B1 strain of newcastle disease virus against cervical cancer cell proliferation is mediated by the increased expression of cytochrome C,autophagy and apoptotic pathways[J].Microb Pathog,2020,147:104438.
4 Jiffry J,Thavornwatanayong T,Rao D,et al.Oncolytic reovirus(pelareorep)induces autophagy in KRAS-mutated colorectal cancer[J].Clin Cancer Res,2021,27(3):865-876.
5 Fernald K,Kurokawa M.Evading apoptosis in cancer[J].Trends Cell Biol,2013,23(12):620-633.
6 Coultas L,Strasser A.The role of the Bcl-2 protein family in cancer[J].Semin Cancer Biol,2003,13(2):115-23.
7 Hersey P,Zhang XD.Overcoming resistance of cancer cells to apoptosis[J].J Cell Physiol,2003,196(1):9-18.
8 Elankumaran S,Rockemann D,Samal SK.Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic Caspase-dependent pathways of cell death[J].J Virol,2006,80(15):7522-7534.
9 Fulda S.Targeting apoptosis for anticancer therapy[J].Semin Cancer Biol,2015,31:84-88.
10 Kalantari A,Farashi Bonab S,Keyvanfar H,et al.Evaluation of apoptosis induction by newcastle disease virus laSota strain in human breast carcinoma cells[J].Arch Razi Inst,2020,75(3):367-376.
11 Yang M,Cao X,Yu MC,et al.Potent antitumor efficacy of ST13 for colorectal cancer mediated by oncolytic adenovirus via mitochondrial apoptotic cell death[J].Hum Gene Ther,2008,19(4):343-353.
12 Koff JL,Ramachandiran S,Bernal-Mizrachi L.A time to kill:targeting apoptosis in cancer[J].Int J Mol Sci,2015,16(2):2942-2955.
13 Whilding LM,Archibald KM,Kulbe H,et al.Vaccinia virus induces programmed necrosis in ovarian cancer cells[J].Mol Ther,2013,21(11):2074-2086.
14 Nichols DB,De Martini W,Cottrell J.Poxviruses utilize multiple strategies to inhibit apoptosis[J].Viruses,2017,9(8):215.
15 Deng L,Yang X,Fan J,et al.IL-24-armed oncolytic vaccinia virus exerts potent antitumor effects via multiple pathways in colorectal cancer[J].Oncol Res,2021,28(6):579-590.
16 Jeong SN,Yoo SY.Novel Oncolytic virus armed with cancer suicide gene and normal vasculogenic gene for improved anti-tumor activity[J].Cancers(Basel),2020,12(5):1070.
17 Zhu W,Zhang H,Shi Y,et al.Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand(TRAIL)inhibits the growth and metastasis of triple-negative breast cancer[J].Cancer Biol Ther,2013,14(11):1016-1023.
18 Hu J,Wang H,Gu J,et al.Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis[J].Acta Biochim Biophys Sin(Shanghai),2018,50(10):1018-1027.
19 Szegezdi E,Logue SE,Gorman AM,et al.Mediators of endoplasmic reticulum stress-induced apoptosis[J].EMBO Rep,2006,7(9):880-885.
20 Faitova J,Krekac D,Hrstka R,et al.Endoplasmic reticulum stress and apoptosis[J].Cell Mol Biol Lett,2006,11(4):488-505.
21 Fabian Z,Csatary CM,Szeberenyi J,et al.p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines[J].J Virol,2007,81(6):2817-2830.
22 Morishima N,Nakanishi K,Takenouchi H,et al.An endoplasmic reticulum stress-specific Caspase cascade in apoptosis.Cytochrome c-independent activation of Caspase-9 by Caspase-12[J].J Biol Chem,2002,277(37):34287-34294.
23 Jia X,Chen Y,Zhao X,et al.Oncolytic vaccinia virus inhibits human hepatocellular carcinoma MHCC97-H cell proliferation via endoplasmic reticulum stress,autophagy and Wnt pathways[J].J Gene Med,2016,18(9):211-219.
24 Tang S,Ning Q,Yang L,et al.Mechanisms of immune escape in the cancer immune cycle[J].Int Immunopharmacol,2020,86:106700.
25 Beatty GL,Gladney WL.Immune escape mechanisms as a guide for cancer immunotherapy[J].Clin Cancer Res,2015,21(4):687-692.
26 Munn DH,Bronte V.Immune suppressive mechanisms in the tumor microenvironment[J].Curr Opin Immunol,2016,39:1-6.
27 Ahmed J,Chard LS,Yuan M,et al.A new oncolytic V accinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery[J].J Immunother Cancer,2020,8(1):e000415.
28 Melchjorsen J.Learning from the messengers:innate sensing of viruses and cytokine regulation of immunity-clues for treatments and vaccines[J].Viruses,2013,5(2):470-527.
29 Stanford MM,Breitbach CJ,Bell JC,et al.Innate immunity,tumor microenvironment and oncolytic virus therapy:friends or foes?[J]Curr Opin Mol Ther,2008,10(1):32-37.
30 Krysko DV,Garg AD,Kaczmarek A,et al.Immunogenic cell death and DAMPs in cancer therapy[J].Nat Rev Cancer,2012,12(12):860-875.
31 Marchini A,Daeffler L,Pozdeev VI,et al.Immune conversion of tumor microenvironment by oncolytic viruses:the protoparvovirus H-1PV case study[J].Front Immunol,2019,10:1848.
32 Hemminki O,Dos Santos JM,Hemminki A.Oncolytic viruses for cancer immunotherapy[J].J Hematol Oncol,2020,13(1):84.
33 Kim Y,Clements DR,Sterea AM,et al.Dendritic cells in oncolytic virus-based anti-cancer therapy[J].Viruses,2015,7(12):6506-6525.
34 Steinman RM,Hemmi H.Dendritic cells:translating innate to adaptive immunity[J].Curr Top Microbiol Immunol,2006,311:17-58.
35 Chaurasiya S,Yang A,Kang S,et al.Oncolytic poxvirus CF33-hNIS-DeltaF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model[J].Oncoimmunology,2020,9(1):1729300.
36 Sivanandam V,LaRocca CJ,Chen NG,et al.Oncolytic viruses and immune checkpoint inhibition:the best of both worlds[J].Mol Ther Oncolytics,2019,13:93-106.
37 Chen L,Han X.Anti-PD-1/PD-L1 therapy of human cancer:past,present,and future[J].J Clin Invest,2015,125(9):3384-3391.
38 Xu F,Jin T,Zhu Y,et al.Immune checkpoint therapy in liver cancer[J].J Exp Clin Cancer Res,2018,37(1):110.
39 Galon J,Bruni D.Approaches to treat immune hot,altered and cold tumours with combination immunotherapies[J].Nat Rev Drug Discov,2019,18(3):197-218.
40 Rajani KR,Vile RG.Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors[J].Viruses,2015,7(11):5889-5901.
41 Dyer A,Baugh R,Chia SL,et al.Turning cold tumours hot:oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference[J].Cancer Gene Ther,2019,26(3-4):59-73.
42 Gujar S,Pol JG,Kroemer G.Heating it up:Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies[J].Oncoimmunology,2018,7(8):e1442169.
43 Mostafa AA,Meyers DE,Thirukkumaran CM,et al.Oncolytic reovirus and immune checkpoint inhibition as a novel immunotherapeutic strategy for breast cancer[J].Cancers(Basel),2018,10(6):205.
44 Longo V,Brunetti O,Azzariti A,et al.Strategies to improve cancer immune checkpoint inhibitors efficacy,other than abscopal effect:a systematic review[J].Cancers(Basel),2019,11(4):539.
45 Saha D,Martuza RL,Rabkin SD.Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma[J].Immunotherapy,2018,10(9):779-786.
46 Goradel NH,Mohajel N,Malekshahi ZV,et al.Oncolytic adenovirus:A tool for cancer therapy in combination with other therapeutic approaches[J].J Cell Physiol,2019,234(6):8636-8646.
47 Nakao S,Arai Y,Tasaki M,et al.Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade[J].Sci Transl Med,2020,12(526):7992.
48 Wei D,Xu J,Liu XY,et al.Fighting cancer with viruses:oncolytic virus therapy in china[J].Hum Gene Ther,2018,29(2):151-159.
49 Printz C.FDA approves new treatment of metastatic melanoma[J].Cancer,2016,122(8):1149.
50 Martin NT,Roy DG,Workenhe ST,et al.Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer[J].Sci Rep,2019,9(1):1865.

[1]	符艳, 颜李丽, 王春雨, 符芳敏, 董华. 2010—2016年琼海市恶性肿瘤流行情况分析[J]. 实用肿瘤学杂志, 2021, 35(5): 396-401.
[2]	陈雪健, 王伟, 周健, 李宁, 张浩鹏, 徐力善. 瑞戈非尼联合哌立福辛诱导人肝癌HepG2细胞凋亡的分子机制研究[J]. 实用肿瘤学杂志, 2021, 35(5): 408-413.
[3]	范琳, 田霖丽, 刘鸣. 单细胞测序技术在头颈部恶性肿瘤中的研究与发展[J]. 实用肿瘤学杂志, 2021, 35(5): 472-475.
[4]	董华, 王定彬, 华婧, 范康琼, 马楠楠, 王兴任. 2016年海南省肿瘤登记地区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2021, 35(4): 344-350.
[5]	陈莉莉, 刘玉琴, 丁高恒, 苏海翔. 甘肃省恶性肿瘤流行情况及防控现状[J]. 实用肿瘤学杂志, 2021, 35(3): 254-257.
[6]	马明瑞, 连洁, 刘超, 娄长杰, 张艳桥. 消化系统肿瘤“免疫治疗前移”的探索[J]. 实用肿瘤学杂志, 2021, 35(3): 258-262.
[7]	国昊楠, 秦韬. MYO10与恶性肿瘤的研究进展[J]. 实用肿瘤学杂志, 2021, 35(3): 273-276.
[8]	潘红艳, 李爱萍, 李强. 脂肪因子Omentin-1与肿瘤相关性的研究[J]. 实用肿瘤学杂志, 2021, 35(3): 282-286.
[9]	王萌萌, 连洁, 李恒震, 张艳桥. 胃肠胰神经内分泌肿瘤的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 154-159.
[10]	胡启辉, 杜毅超, 贺凯, 付文广, 夏先明. 内质网应激在肝癌中的作用[J]. 实用肿瘤学杂志, 2021, 35(2): 160-164.
[11]	郑志远,综述,曲国蕃(审校). 长链非编码RNA SNHG3在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 50-54.
[12]	杨思琦,宋启斌,李清清(综述),姚颐(审校). 靶向抑制FGFRs信号在治疗恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 73-77.
[13]	文洪梅, 陈杨, 石青萍, 任思颖, 高娇, 秦明芳. 2016年云南省肿瘤登记地区恶性肿瘤的发病和死亡分析[J]. 实用肿瘤学杂志, 2020, 34(6): 485-490.
[14]	相智声, 马晶昱, 钟文玲, 陈铁晖, 林永添, 江惠娟, 周衍. 福建省2016年恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2020, 34(6): 491-494.
[15]	李建昕, 沈彬杰, 王璇. 恶性肿瘤社区随访模式的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 540-543.